{"id":4329,"date":"2021-10-15T16:00:00","date_gmt":"2021-10-15T14:00:00","guid":{"rendered":"https:\/\/preview.lifescience-factory.com\/?page_id=4329"},"modified":"2025-04-28T12:47:23","modified_gmt":"2025-04-28T10:47:23","slug":"community","status":"publish","type":"page","link":"https:\/\/preview.lifescience-factory.com\/de\/community\/","title":{"rendered":"Community"},"content":{"rendered":"\n\n
\n\n \n
\n <\/a>\n <\/div>\n\n \n
<\/div>\n\n \n \n
\n \"background\"\n\n \"background\"\n \n \n <\/div>\n \n \n
\n\n
\n\n \n
\n

\n Meet our network <\/h1>\n <\/div>\n\n \n
\n\n \n

Unsere kuratierte Community hilft dir mit Vordenkern, Changemakern und Branchenexperten in Kontakt zu treten und zusammenzuarbeiten. Das Netzwerk versteht sich auf Unternehmertum und auf die Welt der Life Science. Die st\u00e4ndige interdisziplin\u00e4re Interaktion innerhalb dieses \u00d6kosystems stimuliert stets neue Denkweisen und L\u00f6sungen, die unsere Realit\u00e4t neu definieren und anregen.<\/p>\n\n \n \n \n <\/div>\n <\/div>\n <\/div>\n\n<\/div>\n\n\n\n

\n\n
\n
\n
\n

Vorstellung Start-Ups<\/h2>\n <\/div>\n <\/div>\n
\n
\n

Unsere diverse Gr\u00fcnder*innen-Community w\u00e4chst stetig im Herzen G\u00f6ttingens. Erfahre mehr \u00fcber die Start-ups und ihre Geschichten, Erfolge und Herausforderungen. Hier treffen Unternehmertum und Life Science Forschergeist zusammen, die unsere kollaborative Community t\u00e4glich bereichern.<\/p>\n <\/div>\n <\/div>\n <\/div>\n \n

\n
\n
\n
\n

Maker’s Factory user<\/h4>\n

Digity<\/h2>\n <\/div>\n
\n

lab user<\/h4>\n

Cultimate Foods<\/h2>\n <\/div>\n
\n

Maker’s Factory user<\/h4>\n

Waterscope<\/h2>\n <\/div>\n
\n

lab user alumni<\/h4>\n

Ucaneo Biotech<\/h2>\n <\/div>\n
\n

lab user<\/h4>\n

Cinference<\/h2>\n <\/div>\n
\n

lab user<\/h4>\n

Curexsys GmbH \u2013 Pure to Cure<\/h2>\n <\/div>\n
\n

lab user<\/h4>\n

myotwin<\/h2>\n <\/div>\n
\n

lab user<\/h4>\n

Avocet Bio<\/h2>\n <\/div>\n
\n

lab user<\/h4>\n

BrainQR<\/h2>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n
\n
\n

Maker’s Factory user<\/h4>\n

Digity<\/h2>\n
<\/div>\n <\/div>\n
\n
\n \"Digity\n <\/div>\n
\n

Digity ist ein auf die Hand spezialisiertes Technologie-Startup mit automatisierten Prozessen, um die menschliche Hand mit Exoskeletten auszustatten. Denn unsere H\u00e4nde definieren, wie wir mit der Welt interagieren. Unsere Mission ist daher sicherzustellen, dass diese immer gesund, gesch\u00fctzt und produktiv sind. Unsere Patente und eine digitale Hintergrundtechnologie erm\u00f6glichen es uns, unsere Exoskelette an unterschiedliche Bereiche anzupassen. Unser Startprodukt ARTUS adressiert den Arbeitsschutz und Ergonomie der Finger in manuellen T\u00e4tigkeiten in der Industrie und Handwerk. Das interdisziplin\u00e4re Team aus den Ingenieurswissenschaften, Orthop\u00e4dietechnik und Betriebswirtschaft ist aus einem EXIST-Forschungstransfer hervorgegangen und will aus G\u00f6ttingen heraus einen Marktf\u00fchrer aufbauen, der echte L\u00f6sungen f\u00fcr handbezogene Belange bietet.<\/p>\n\n \n \n <\/span>mehr erfahren<\/span>\n <\/a>\n \n <\/div>\n <\/div>\n <\/div>\n

\n
\n

lab user<\/h4>\n

Cultimate Foods<\/h2>\n
<\/div>\n <\/div>\n
\n
\n \"Cultimate\n <\/div>\n
\n

Cultimate Foods creates a game-changing ingredient based on cultivated fat in a sustainable and ethical way.
\nTheir unique solution enriches plant-based meat alternatives with authentic taste, mouthfeel, and texture. They believe that the future of meat is hybrid – a combination of plant-based proteins and their fat alternative product.<\/p>\n\n \n \n <\/span>mehr erfahren<\/span>\n <\/a>\n \n <\/div>\n <\/div>\n <\/div>\n

\n
\n

Maker’s Factory user<\/h4>\n

Waterscope<\/h2>\n
<\/div>\n <\/div>\n
\n
\n \"Waterscope\n <\/div>\n
\n

Globally, water-borne bacterial infections lead to half a million diarrhoeal-related deaths each year\u2014more than 2,000 deaths every day. This is more than malaria and HIV-related deaths combined. WaterScope seeks to overcome global water inequality by breaking barriers to reliable bacterial testing. The team has developed an innovative testing device that can reliably and automatically identify bacterial presence in water in as little as 18 hours. The testing data is provided in real time and is uploaded to a central dashboard, connecting users in over 165 countries around the world.<\/p>\n\n \n \n <\/span>mehr erfahren<\/span>\n <\/a>\n \n <\/div>\n <\/div>\n <\/div>\n

\n
\n

lab user alumni<\/h4>\n

Ucaneo Biotech<\/h2>\n
<\/div>\n <\/div>\n
\n
\n \"Ucaneo\n <\/div>\n
\n

We are building the world’s first biotechnological Direct Air Capture (DAC) system with the goal to to capture 1% of the global CO2 emissions by 2035!<\/p>\n

Leveraging novel membranes and enzymes significantly reduces the energy consumption by lowering the conventional Direct Air Capture reaction temperature from up to 900\u00b0C to room temperature and avoiding active air intake. This enables massive cost savings and a sustainable reduction of CO2 in the atmosphere. <\/p>\n

Using the most modern equipment and S1 lab as well as the makerspace we found the perfect place at the Life Science Factory to develop our biotech hardware solution.<\/p>\n\n \n \n <\/span>Mehr erfahren<\/span>\n <\/a>\n \n <\/div>\n <\/div>\n <\/div>\n

\n
\n

lab user<\/h4>\n

Cinference<\/h2>\n
<\/div>\n <\/div>\n
\n
\n \"Cinference\n <\/div>\n
\n

Ca. 50% aller Therapien haben eine Proteinkomponente, aber die therapeutische Proteinentwicklung ist sehr kostspielig und dauert 2-3 Jahre. Cinference ist ein life-science Biotech-startup welches therapeutische Proteine designt. Cinferences Mission ist es den Proteinentwicklungsprozess auf 1-2 Monate zu verk\u00fcrzen. Daf\u00fcr nutzt das Unternehmen dateneffiziente Algorithmen in Kombination mit gro\u00dfen AI-Modelle welche auf Millionen von Proteinsequenzen trainiert wurden, um 99% des Designprozesses digital durchzuf\u00fchren und Designparameter simultan zu optimieren. Das junge Startup befindet sich auf Wachstumskurs und stellt verst\u00e4rkt Biologie-Talent ein, um an den ersten Partnerschaften im Pharmabereich zu arbeiten. Cinference plant im M\u00e4rz n\u00e4chsten Jahres in die Life Science Factory einzuziehen und das neu gebaute Labor zu nutzen.<\/p>\n\n \n \n <\/span>Mehr erfahren<\/span>\n <\/a>\n \n <\/div>\n <\/div>\n <\/div>\n

\n
\n

lab user<\/h4>\n

Curexsys GmbH \u2013 Pure to Cure<\/h2>\n
<\/div>\n <\/div>\n
\n
\n \"Curexsys\n <\/div>\n
\n

Curexsys is active in the anti-aging field and develops exosomes as innovative therapeutics to cure age-related diseases. <\/h3>\n

Curexsys is active in the anti-aging field and combats age-related defects with exosomes derived from induced mesenchymal stem cells (iMSCs).  Exosomes constitute a new therapeutic principle clearly distinct from classical small or large molecule compounds or cell therapy. They are small vesicles that are naturally released from a cell. They contain proteins, nucleic acids and metabolites, which carry information from secreting to receiving cells. Exosomes have immunomodulatory and anti-inflammatory effects.<\/p>\n

Due to increasingly aging societies, anti-aging therapies are of great interest to the pharma industry, health care providers and aging populations, and the Curexsys exosome platform will serve the arising demand of pure and functional exosomes in pharma industry. With the leading technology for highly selective and traceless purification of extracellular vesicles with low-affinity Fabs, Curexsys uses a unique technology to generate products for clinical applications, matching medical needs with increasing patient numbers in multiple disease areas.<\/p>\n\n \n \n <\/span>Mehr erfahren<\/span>\n <\/a>\n \n <\/div>\n <\/div>\n <\/div>\n

\n
\n

lab user<\/h4>\n

myotwin<\/h2>\n
<\/div>\n <\/div>\n
\n
\n \"Mytotwin\n <\/div>\n
\n

Neugestaltung der Arzneimittelentwicklung durch kontinuierliche Echtzeit- und High-Content-Analyse<\/h3>\n

Die Entwicklung und Testung neuer Arzneimittel bis hin zur Zulassung sind sehr kostenintensiv. Hinzu kommt, dass neue regulatorische Verordnungen die Anzahl an Tierversuchen in Zukunft verringern sollen. Das Biotech Start-up myotwin verwendet stammzell-basierte<\/em> Herzmuskelgewebe in einer eigens entwickelten Messinfrastruktur. Dies erlaubt einen deutlich fr\u00fcheren und umfangreichen Einblick in die menschliche Reaktion auf einen Wirkstoff. Dadurch k\u00f6nnen neue Wirkstoffe ohne Tierversuche in der Pr\u00e4klinik getestet werden und die Sicherheit in klinischen Studien erh\u00f6ht werden. myotwin nutzt seinen umfangreichen Daten auch zum Aufbau eines Digital Twin des menschlichen Herzmuskels, , um zuk\u00fcnftig auch Services im Bereich der pr\u00e4diktiven Wirkstoffentwicklung anzubieten.<\/p>\n\n \n \n <\/span>Mehr erfahren<\/span>\n <\/a>\n \n <\/div>\n <\/div>\n <\/div>\n

\n
\n

lab user<\/h4>\n

Avocet Bio<\/h2>\n
<\/div>\n <\/div>\n
\n
\n \"Avocet\n <\/div>\n
\n

Pionierarbeit bei neuartigen RNA-basierten Therapeutika<\/h3>\n

Bei Avocet Bio ist unsere Mission klar: Wir wollen Neuland betreten, indem wir unsere Plattformtechnologie der RNA-Modulation als Schl\u00fcsselansatz f\u00fcr die Therapie verschiedener Krankheiten nutzen.<\/p>\n

Als Biotech-Startup gehen wir einige der dr\u00e4ngendsten globalen Gesundheitsherausforderungen an, einschlie\u00dflich respiratorischer Virusinfektionen, w\u00e4hrend wir das Potenzial der RNA-Modulation auf andere medizinische Bereiche erweitern.<\/p>\n

Unser langfristiges Ziel ist es, ein vielf\u00e4ltiges Portfolio an RNA-basierten Therapeutika aufzubauen, das bestehende Behandlungsl\u00fccken adressiert und neue, effektivere L\u00f6sungen f\u00fcr Patienten bietet.<\/p>\n\n \n \n <\/span>Mehr erfahren<\/span>\n <\/a>\n \n <\/div>\n <\/div>\n <\/div>\n

\n
\n

lab user<\/h4>\n

BrainQR<\/h2>\n
<\/div>\n <\/div>\n
\n
\n \"BrainQR\n <\/div>\n
\n

brainQr makes disordered proteins druggable<\/h3>\n

brainQr Therapeutics is developing next-generation therapies for major human diseases by targeting disordered proteins, a vast and previously largely undruggable class of biomolecules. Our mission is to harness cutting-edge scientific innovation to pioneer novel treatment strategies that address urgent unmet medical needs. <\/span>brainQr’s AI-IDP platform enables breakthrough therapies for dynamic disordered proteins, unlocking new possibilities in neurodegeneration and oncology.<\/span><\/p>\n\n \n \n <\/span>Mehr erfahren<\/span>\n <\/a>\n \n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\n\n<\/div>\n\n\n\n

\n\n\n
\n
\n

Join our Start-ups<\/h2>\n <\/div>\n <\/div>\n \n\n \n<\/div>\n\n\n\n
\n\n\n
\n
\n\n\n
\n\n\n
\n

GliTTher: Lab Head\/Platform Manager (100%)<\/span><\/h3>\n <\/div>\n \n \n
\n\n\n \n\n \n
\n

Job Title: <\/strong> Lab Head\/Platform Manager (100%)
\n Company: <\/strong> GliTTher Technologies
\n Location: <\/strong> G\u00f6ttingen, Niedersachsen, Germany
\n Start Date: <\/strong> April or August 2025<\/p>\n

About GliTTher <\/strong>
\nVisit their website<\/a>
\nGliTTher is an innovative start-up dedicated to advancing treatments and diagnostics for
\ncancer-initiating cells. Located in G\u00f6ttingen, Germany, we leverage a pioneering
\ntechnology platform to identify and develop new therapies targeting cancer-initiating cells.<\/p>\n

Role Summary <\/strong>
\nWe are seeking a dynamic Lab Head\/Platform Manager to lead our research efforts in
\nglioma-initiating cells. In this role, you will oversee the characterization of these cells,
\nutilizing FACS sorting and validating their stemness properties. Additionally, you will lead
\nthe screening for novel therapeutic compounds, advancing GliTTher\u2019s proprietary platform
\nto uncover potential new treatments for glioma.<\/p>\n

Key Responsibilities <\/strong>
\n\u2022 Lead the setup and management of GliTTher’s technology platform focused on
\nglioma-initiating cells
\n\u2022 Conduct FACS sorting and stemness validation of glioma-initiating cells
\n\u2022 Drive screening and testing of GliTTher-identified molecules as potential glioma
\ntreatments
\n\u2022 Manage laboratory operations, ensuring high standards of research quality and
\nintegrity<\/p>\n

Required Expertise <\/strong>
\n\u2022 Cellular Biology <\/strong> \u2013 Proficiency in cellular mechanisms and cancer biology
\n\u2022 Cancer Research <\/strong> \u2013 Solid background in cancer research methodologies
\n\u2022 Flow Cytometry <\/strong> \u2013 Strong experience in FACS sorting and data interpretation<\/p>\n

Technical Skills <\/strong>
\n\u2022 Primary cell culture
\n\u2022 Flow cytometry
\n\u2022 Microscopy
\n\u2022 Cloning
\n\u2022 Molecular biology techniques
\n\u2022 Inhibitor testing<\/p>\n

Application Deadline <\/strong>
\nSubmit your CV and a statement of motivation by March 31, 2025 <\/strong> . Please email your
\napplication to sammy@glitther.com<\/a> and virginie@glitther.com<\/a><\/p>\n <\/div>\n \n\n \n \n \n\n \n \n\n \n\n <\/div>\n \n\n <\/div>\n\n\n <\/div>\n <\/div>\n\n\n<\/div>\n\n\n\n

\n \n
\n
\n\n
<\/div>\n \n <\/div>\n\n \n <\/div>\n\n<\/div>\n\n\n\n
\n\n
\n
\n
\n

get in touch with our mentors<\/h2>\n <\/div>\n <\/div>\n
\n
\n

Erhalte fachkundige Unterst\u00fctzung durch unsere Mentoren und Investoren. Gerade Start-ups in einer fr\u00fchen Phase ben\u00f6tigen bedarfsgerechte Unterst\u00fctzung bei ihren Herausforderungen. Unsere Experten sind selbst erfolgreiche Life-Science-Gr\u00fcnder*innen, Investoren oder Wissenschaftler*innen, die begeistert ihre spezifischen Fachkenntnisse teilen und helfen innovative Projekte nachhaltig aufzubauen. <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n \n<\/div>\n\n\n\n

\n\n \n\n
\n\n \n \n
\n\n\n
\n \n \"\"\n\n <\/a>\n <\/div>\n \n\n

Dr. Grit Zahn<\/h3>\n \n\n

Head of Research at Eternygen GmbH I Drug Development, Company building, technology transfer<\/h5>\n \n\n

Grit ist Biochemikerin und arbeitet seit mehr als 20 Jahren im Drug Development. Dabei hat sie schon in verschiedenen Institutionen und Firmen gearbeitet, angefangen in der Forschung an der Charit\u00e9 in Berlin, in der Medikamentenentwicklung beim BioTechunternehmen Jerini AG, was ein Produkt bis zur Marktreife entwickelt hat, im Technologietransfer bei der ipal GmbH bis hin zur Eternygen GmbH. Hier ist sie als Head of Research t\u00e4tig und ber\u00e4t dar\u00fcber hinaus auch weitere Biotechunternehmen.<\/p>\n\n\n <\/span>LinkedIn Profil Grit Zahn<\/span><\/a>\n \n <\/div>\n \n

\n\n\n
\n \n \"\"\n\n <\/a>\n <\/div>\n \n\n

Julia Schomburg<\/h3>\n \n\n

Investment Manager at Arkadien Finanz I Investor Readiness, Business Structure, Team Development<\/h5>\n \n\n

Julia Schomburg ist Kommunikations\u00f6konomin und war mehrere Jahre in Werbeagenturen t\u00e4tig. Seit \u00fcber 15 Jahren bringt sie ihre Erfahrung als Investment Managerin bei Arkadien Finanz ein. Mit ihrem umfassenden Branchenwissen unterst\u00fctzt sie Start-ups vor allem in den Bereichen Investor Readiness, Gesch\u00e4ftsaufbau und Teamentwicklung.<\/p>\n\n\n <\/span>LinkedIn Profil Julia Schomburg<\/span><\/a>\n \n <\/div>\n \n

\n\n\n
\n \n \"\"\n\n <\/a>\n <\/div>\n \n\n

Daniel Schuppmann<\/h3>\n \n\n

Lawyer for IP & Tech Law at NEUWERK I Life Sciences, Licensing, Product Development Support<\/h5>\n \n\n

Daniel ist Jurist und ber\u00e4t umfassend zu Fragen des Technologie- und geistigen Eigentumsrechts, Datenschutzes sowie zu vertraglichen Themen. Sein Schwerpunkt liegt auf der Unterst\u00fctzung von Life-Science-Unternehmen \u2013 insbesondere beim Schutz und der Lizenzierung ihrer Technologien sowie bei der rechtlichen Begleitung entlang des gesamten Produktentwicklungszyklus.<\/p>\n\n\n <\/span>LinkedIn Profil Daniel Schuppmann<\/span><\/a>\n \n <\/div>\n <\/div>\n \n\n<\/div>\n\n\n\n\n

\n
\n\n
\n\n
\n\n
\n

mehr erfahren?<\/h2>\n <\/div>\n\n
\n

Dann schlie\u00dfe ein Community Ticket ab und erhalte Zugang zu dem kompletten Netzwerk.<\/p>\n <\/div>\n\n

\n <\/span>Angebot<\/span><\/a>\n <\/div>\n\n <\/div>\n\n <\/div>\n\n <\/div>\n<\/div>\n\n\n\n\n\n\n
\n\n
\n
\n

shoutout to our partners!<\/h2>\n <\/div>\n <\/div>\n \n
\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n
\n \n \"\"\/\n <\/a>\n <\/div>\n <\/div>\n \n<\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":35,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-4329","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/preview.lifescience-factory.com\/de\/wp-json\/wp\/v2\/pages\/4329","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/preview.lifescience-factory.com\/de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/preview.lifescience-factory.com\/de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/preview.lifescience-factory.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/preview.lifescience-factory.com\/de\/wp-json\/wp\/v2\/comments?post=4329"}],"version-history":[{"count":217,"href":"https:\/\/preview.lifescience-factory.com\/de\/wp-json\/wp\/v2\/pages\/4329\/revisions"}],"predecessor-version":[{"id":57275,"href":"https:\/\/preview.lifescience-factory.com\/de\/wp-json\/wp\/v2\/pages\/4329\/revisions\/57275"}],"wp:attachment":[{"href":"https:\/\/preview.lifescience-factory.com\/de\/wp-json\/wp\/v2\/media?parent=4329"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}